227 related articles for article (PubMed ID: 37175614)
21. Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state.
Fallahi-Sichani M; Becker V; Izar B; Baker GJ; Lin JR; Boswell SA; Shah P; Rotem A; Garraway LA; Sorger PK
Mol Syst Biol; 2017 Jan; 13(1):905. PubMed ID: 28069687
[TBL] [Abstract][Full Text] [Related]
22. Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors.
Schreuer M; Meersseman G; Van Den Herrewegen S; Jansen Y; Chevolet I; Bott A; Wilgenhof S; Seremet T; Jacobs B; Buyl R; Maertens G; Neyns B
J Transl Med; 2016 Apr; 14():95. PubMed ID: 27095081
[TBL] [Abstract][Full Text] [Related]
23. Pro-Apoptotic Activity of MCL-1 Inhibitor in Trametinib-Resistant Melanoma Cells Depends on Their Phenotypes and Is Modulated by Reversible Alterations Induced by Trametinib Withdrawal.
Hartman ML; Koziej P; Kluszczyńska K; Czyz M
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835493
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
Kim KB; Kefford R; Pavlick AC; Infante JR; Ribas A; Sosman JA; Fecher LA; Millward M; McArthur GA; Hwu P; Gonzalez R; Ott PA; Long GV; Gardner OS; Ouellet D; Xu Y; DeMarini DJ; Le NT; Patel K; Lewis KD
J Clin Oncol; 2013 Feb; 31(4):482-9. PubMed ID: 23248257
[TBL] [Abstract][Full Text] [Related]
25. "RB-reactivator screening" as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist).
Sakai T
Pharmacol Ther; 2022 Aug; 236():108234. PubMed ID: 35732246
[TBL] [Abstract][Full Text] [Related]
26. Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).
Atkinson V; Sandhu S; Hospers G; Long GV; Aglietta M; Ferrucci PF; Tulyte S; Cappellini GCA; Soriano V; Ali S; Poprach A; Cesas A; Rodriguez-Abreu D; Lau M; de Jong E; Legenne P; Stein D; King B; van Thienen JV
Melanoma Res; 2020 Jun; 30(3):261-267. PubMed ID: 31895752
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
[TBL] [Abstract][Full Text] [Related]
28. Harnessing autophagy to overcome mitogen-activated protein kinase kinase inhibitor-induced resistance in metastatic melanoma.
Verykiou S; Alexander M; Edwards N; Plummer R; Chaudhry B; Lovat PE; Hill DS
Br J Dermatol; 2019 Feb; 180(2):346-356. PubMed ID: 30339727
[TBL] [Abstract][Full Text] [Related]
29. Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation.
Teshima Y; Kizaki M; Kurihara R; Kano R; Harumiya M
Int J Clin Oncol; 2020 Oct; 25(10):1870-1878. PubMed ID: 32699976
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
Kundu A; Quirit JG; Khouri MG; Firestone GL
Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
[TBL] [Abstract][Full Text] [Related]
31. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
Si L; Zhang X; Shin SJ; Fan Y; Lin CC; Kim TM; Dechaphunkul A; Maneechavakajorn J; Wong CS; Ilankumaran P; Lee DY; Gasal E; Li H; Guo J
Eur J Cancer; 2020 Aug; 135():31-38. PubMed ID: 32534242
[TBL] [Abstract][Full Text] [Related]
32. Trametinib: a novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma.
Chung C; Reilly S
Am J Health Syst Pharm; 2015 Jan; 72(2):101-10. PubMed ID: 25550132
[TBL] [Abstract][Full Text] [Related]
33. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
34. Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with
Tawbi HA; Robert C; Brase JC; Gusenleitner D; Gasal E; Garrett J; Savchenko A; Görgün G; Flaherty KT; Ribas A; Dummer R; Schadendorf D; Long GV; Nathan PD; Ascierto PA
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35728875
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study.
Nebhan CA; Johnson DB; Sullivan RJ; Amaria RN; Flaherty KT; Sosman JA; Davies MA
Oncologist; 2021 Sep; 26(9):731-e1498. PubMed ID: 33861486
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous suppression of MITF and BRAF V600E enhanced inhibition of melanoma cell proliferation.
Kido K; Sumimoto H; Asada S; Okada SM; Yaguchi T; Kawamura N; Miyagishi M; Saida T; Kawakami Y
Cancer Sci; 2009 Oct; 100(10):1863-9. PubMed ID: 19659611
[TBL] [Abstract][Full Text] [Related]
37. Improved survival with MEK inhibition in BRAF-mutated melanoma.
Flaherty KT; Robert C; Hersey P; Nathan P; Garbe C; Milhem M; Demidov LV; Hassel JC; Rutkowski P; Mohr P; Dummer R; Trefzer U; Larkin JM; Utikal J; Dreno B; Nyakas M; Middleton MR; Becker JC; Casey M; Sherman LJ; Wu FS; Ouellet D; Martin AM; Patel K; Schadendorf D;
N Engl J Med; 2012 Jul; 367(2):107-14. PubMed ID: 22663011
[TBL] [Abstract][Full Text] [Related]
38. Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy.
Latimer NR; Bell H; Abrams KR; Amonkar MM; Casey M
Cancer Med; 2016 May; 5(5):806-15. PubMed ID: 27172483
[TBL] [Abstract][Full Text] [Related]
39. Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.
Kong X; Kuilman T; Shahrabi A; Boshuizen J; Kemper K; Song JY; Niessen HWM; Rozeman EA; Geukes Foppen MH; Blank CU; Peeper DS
Nature; 2017 Oct; 550(7675):270-274. PubMed ID: 28976960
[TBL] [Abstract][Full Text] [Related]
40. Trametinib in the treatment of melanoma.
Thota R; Johnson DB; Sosman JA
Expert Opin Biol Ther; 2015 May; 15(5):735-47. PubMed ID: 25812921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]